Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
CAMBRIDGE, MA—KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), currently trading at $10.71 and showing a strong 12.38% return over the past week, recently saw its Chief Executive Officer, Benjamin L. Palleiko, engage in a notable stock transaction. According to InvestingPro analysis, the stock’s RSI indicates overbought territory, with 12 additional key insights available to subscribers. According to a recent SEC filing, Palleiko sold 5,104 shares of KalVista common stock on February 18, 2025, at an average price of $9.8242 per share, resulting in a total transaction value of $50,142. With analyst price targets ranging from $18 to $39, the stock currently trades significantly below consensus expectations.
This sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) and performance stock units (PSUs), as noted in the filing. It was not a discretionary sale by Palleiko.
Additionally, on February 17, 2025, Palleiko acquired 9,363 shares of common stock through the exercise of RSUs, without any monetary consideration, as part of his compensation package. These transactions leave Palleiko with a direct ownership of 278,855 shares in KalVista Pharmaceuticals.
In other recent news, KalVista Pharmaceuticals Inc. has been the focus of several analyst reports and regulatory developments. JMP Securities maintained a Market Outperform rating for the company with a price target of $19.00, emphasizing the potential of KalVista’s oral on-demand drug, sebetralstat, for treating hereditary angioedema (HAE). Analysts noted that the HAE market is undervalued and expect sebetralstat to capture a significant portion due to its convenience over injectable treatments. In addition, TD Cowen initiated coverage with a Buy rating and a higher price target of $30.00, projecting peak sales for sebetralstat to exceed $750 million.
Furthermore, Japan’s Ministry of Health, Labour and Welfare granted Orphan Drug Designation to sebetralstat, and a New Drug Application has been submitted in Japan. The application is based on the KONFIDENT phase 3 trial, which involved 136 patients across 20 countries. KalVista has also submitted regulatory applications to the U.S. FDA and European Medicines Agency, with a U.S. Prescription Drug User Fee Act goal date set for June 17, 2025. These developments underscore KalVista’s strategic focus on addressing unmet needs in HAE treatment through its oral therapy option.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.